New Edge Advisors, LLC Moleculin Biotech, Inc. Transaction History

New Edge Advisors, LLC

  • $11.2 Billion
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$0.41 - $0.86 $0 - $1
2 New
2 $0

Others Institutions Holding MBRX

# of Institutions
2
Shares Held
3.35K
Call Options Held
0
Put Options Held
0
View Full List

About Moleculin Biotech, Inc.

MBRX Quotes by TradingView
  • Ticker MBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,606,700
  • Market Cap $124M
  • Description
  • Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....
More about MBRX
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email